Rheumatology and Immunology Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Rheumatology and Immunology. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Rheumatology and Immunology Indian Medical PG Question 1: Match the following drugs with the targets of their actions:
Drugs:
A. Trastuzumab
B. Infliximab
C. Sirolimus
D. Imatinib
Targets:
1. BCR-ABL tyrosine kinase
2. mTOR
3. TNF alpha
4. HER2/neu
- A. A-2, B-3, C-1, D-4
- B. A-3, B-4, C-2, D-1
- C. A-4, B-3, C-1, D-2
- D. A-4, B-3, C-2, D-1 (Correct Answer)
Rheumatology and Immunology Explanation: ***Correct Answer: A-4, B-3, C-2, D-1***
- **Trastuzumab** (Herceptin) is a **monoclonal antibody** that targets the **HER2/neu receptor (4)** [1], [2], commonly overexpressed in certain breast cancers and gastric cancers.
- **Infliximab** is another **monoclonal antibody** that specifically targets and neutralizes **TNF-alpha (3)**, an inflammatory cytokine, making it useful in treating autoimmune diseases like rheumatoid arthritis and Crohn's disease.
- **Sirolimus** is an **immunosuppressant** drug that inhibits the mammalian target of rapamycin (**mTOR (2)**), a protein kinase involved in cell growth and proliferation, used in transplant medicine and as an anticancer agent.
- **Imatinib** is a **tyrosine kinase inhibitor** that primarily targets the **BCR-ABL fusion protein (1)** [1], [2], which is characteristic of chronic myeloid leukemia.
*Incorrect: A-2, B-3, C-1, D-4*
- This option incorrectly matches Trastuzumab with mTOR and Sirolimus with BCR-ABL, which are not their primary targets.
- Trastuzumab targets HER2/neu [1], [2], and Sirolimus targets mTOR.
*Incorrect: A-3, B-4, C-2, D-1*
- This option incorrectly matches Trastuzumab with TNF-alpha and Infliximab with HER2/neu.
- Infliximab targets TNF-alpha, and Trastuzumab targets HER2/neu [1], [2].
*Incorrect: A-4, B-3, C-1, D-2*
- This option incorrectly matches Sirolimus with BCR-ABL and Imatinib with mTOR.
- Sirolimus inhibits mTOR, and Imatinib inhibits BCR-ABL [1], [2].
Rheumatology and Immunology Indian Medical PG Question 2: Which of the following conditions is most commonly associated with disease activity in Systemic Lupus Erythematosus (SLE)?
- A. Neutropenia
- B. Thrombocytopenia
- C. Autoimmune Hemolytic anemia
- D. Lymphopenia (Correct Answer)
Rheumatology and Immunology Explanation: ***Lymphopenia***
- **Lymphopenia** (low lymphocyte count) is the most common hematological manifestation associated with active SLE, occurring in approximately 50-80% of patients [1].
- It is often seen in individuals with active disease due to increased peripheral destruction of lymphocytes or their sequestration and redistribution.
*Autoimmune Hemolytic anemia*
- While **autoimmune hemolytic anemia (AIHA)** can occur in SLE, it is less common than lymphopenia, affecting about 5-10% of patients [1].
- AIHA is characterized by the destruction of red blood cells by autoantibodies, leading to **anemia**.
*Thrombocytopenia*
- **Thrombocytopenia** (low platelet count) is another hematologic manifestation of SLE, occurring in 10-25% of patients [1].
- It is caused by autoantibodies directed against platelets, leading to their premature destruction.
*Neutropenia*
- **Neutropenia** (low neutrophil count) is observed in about 10-15% of SLE patients.
- Although it can be a sign of active disease, it is less frequent than lymphopenia [1].
Rheumatology and Immunology Indian Medical PG Question 3: ANA (antinuclear antibody) is seen in all except:
- A. Systemic sclerosis
- B. Sjogren's syndrome
- C. RA (Correct Answer)
- D. SLE
Rheumatology and Immunology Explanation: ***RA***
- While ANA can be positive in a small percentage of RA patients, it is **not a characteristic feature** of rheumatoid arthritis and is found in only 30–50% of cases [1].
- The primary diagnostic markers for RA are **rheumatoid factor (RF)** and **anti-citrullinated protein antibody (ACPA)**.
*Systemic sclerosis*
- **Antinuclear antibodies (ANA)** are present in over 90% of patients with systemic sclerosis, often with specific patterns like nucleolar or centromere [1].
- This makes ANA a key diagnostic and classification criterion for the disease.
*Sjogren's syndrome*
- **ANA is positive in 80-90%** of patients with Sjögren's syndrome, making it a very common finding [1].
- Specific autoantibodies like anti-Ro (SSA) and anti-La (SSB) are also frequently present alongside ANA [1].
*SLE*
- **ANA is highly sensitive for SLE**, being positive in over 95% of patients with systemic lupus erythematosus [1].
- A negative ANA virtually rules out SLE, making it a crucial screening test [2].
Rheumatology and Immunology Indian Medical PG Question 4: All of the following are pattern recognition receptors for extracellular or ingested microbes, except:
- A. Toll-like receptors (TLRs) - Detect pathogen-associated molecular patterns (PAMPs).
- B. NOD-like receptors (NLRs) - Intracellular sensors for microbial components.
- C. Killer-cell immunoglobulin receptors (KIRs) - Recognize MHC class I molecules on host cells. (Correct Answer)
- D. C-type lectin receptors (CLRs) - Recognize carbohydrate structures on microbes.
Rheumatology and Immunology Explanation: ***Killer-cell immunoglobulin receptors (KIRs)***
- KIRs are primarily involved in regulating **natural killer (NK) cells**, not in recognizing microbes [1].
- They primarily interact with **MHC class I molecules** and play a role in **immune surveillance**, rather than pattern recognition of pathogens [1].
*NOD-like receptors (NLRs)*
- NLRs detect **intracellular pathogens** and damaged cells, playing a crucial role in **innate immunity** [2].
- They initiate responses to **bacterial peptidoglycans** and work in the recognition of microbial patterns [2].
*Toll-like receptors (TLRs)*
- TLRs are well-known for recognizing **extracellular microbes** and activate the immune response upon pathogen detection [3].
- They are critical in detecting **lipopolysaccharides (LPS)** and **viral nucleic acids** to elicit immune responses.
*C-type lectin receptors (CLRs)*
- CLRs specifically recognize **carbohydrate structures** on pathogens, playing a key role in **innate immune responses** [3].
- They are important in identifying **fungi** and **bacteria**, enhancing phagocytosis and cytokine production.
**References:**
[1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 200-201.
[2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 196.
[3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 200.
Rheumatology and Immunology Indian Medical PG Question 5: What is the mechanism of action of Tocilizumab?
- A. TNF Alpha inhibition
- B. IL-18 inhibition
- C. Inhibits binding of IL-6 to its receptor IL-6R (Correct Answer)
- D. Inhibits binding of IL-1
- E. IL-17 inhibition
Rheumatology and Immunology Explanation: ***Inhibits binding of IL-6 to its receptor IL-6R***
- **Tocilizumab** is a **monoclonal antibody** that specifically targets the **interleukin-6 (IL-6) receptor**.
- By blocking IL-6 from binding to its receptor, Tocilizumab **inhibits IL-6 mediated signaling**, thereby reducing inflammation and immune responses.
*TNF Alpha inhibition*
- **TNF-alpha inhibitors** (e.g., adalimumab, infliximab) target **tumor necrosis factor-alpha**, a different pro-inflammatory cytokine.
- While both TNF-alpha and IL-6 are involved in inflammatory diseases, their signaling pathways and therapeutic targets are distinct.
*IL-18 inhibition*
- **IL-18** is another pro-inflammatory cytokine, but Tocilizumab does **not directly target** or inhibit its activity.
- Drugs that target IL-18 or its pathways are distinct from those targeting IL-6.
*IL-17 inhibition*
- **IL-17 inhibitors** (e.g., secukinumab, ixekizumab) are biologics that target **interleukin-17**, particularly useful in psoriasis and ankylosing spondylitis.
- Tocilizumab's mechanism is specific to **IL-6**, not IL-17.
*Inhibits binding of IL-1*
- **Interleukin-1 (IL-1)** is a key mediator of inflammation, but specific **IL-1 inhibitors** (e.g., anakinra, canakinumab) act by blocking IL-1 or its receptor.
- Tocilizumab's mechanism is specific to the **IL-6 cytokine-receptor interaction**, not IL-1.
More Rheumatology and Immunology Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
